The Benchmark Company downgraded Codexis from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | Buy → Hold | The Benchmark Company | |
| 6/3/2024 | $5.00 | Buy | Jefferies |
| 5/30/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/29/2024 | Hold → Buy | The Benchmark Company | |
| 11/7/2023 | Buy → Hold | The Benchmark Company | |
| 8/7/2023 | $21.00 → $4.00 | Outperform → Market Perform | TD Cowen |
| 5/9/2023 | Buy → Neutral | H.C. Wainwright | |
| 3/31/2022 | $35.00 | Overweight | Piper Sandler |
SC 13G - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G - CODEXIS, INC. (0001200375) (Subject)
4 - CODEXIS, INC. (0001200375) (Issuer)
3 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
The Benchmark Company downgraded Codexis from Buy to Hold
Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00
Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies
REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 23,000 shares of Codexis common stock and (ii) 11,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nasdaq
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 168,400 shares of Codexis common stock and (ii) 39,750 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nasd
8-K - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
10-Q - CODEXIS, INC. (0001200375) (Filer)
REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies
REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company's Board of Directors. "We are thrilled to have Raymond join the Codexis Board of Directors. He will be an invaluable resource to Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "Raymond brings a deep understanding of the commercial and regulatory landscape as well as direct experience in oligonucleotide manufacturing." "Codexis and its ECO Synthesis platform represent the next generation of innovat
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligon
—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany.
Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "Codexis had a strong third quarter, in which we surpassed product revenue goals, welcomed two new, high